Auxilium Pharmaceuticals, Inc. has submitted a BLA to the FDA for Xiaflex (clostridial collagenase for injection), a novel orphan-designated biologic for the treatment of Dupuytren’s contracture. “This BLA submission is a significant regulatory milestone for Xiaflex,” said Armando Anido, chief executive officer and president of Auxilium. “There currently are no approved non-surgical treatments available for Dupuytren’s contracture, which can be a debilitating dis...